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Abstract
Background: Viral hepatitis is a serious health burden worldwide. To date, few reports have addressed the prevalence of
hepatitis A, B, C, and E in China. Therefore, the general epidemiological parameters of viral hepatitis remain unknown.
Principal Findings: In this cross-sectional study, we performed a serological prevalence analysis of viral hepatitis A, B, C, and
E in 8,762 randomly selected Chinese subjects, which represented six areas of China. The overall prevalence of anti-Hepatitis
C virus antibody (anti-HCV) was 0.58%, which was much lower than was estimated by WHO. The prevalences of Hepatitis B
virus surface antigen (HBsAg), anti-Hepatitis B virus surface protein antibody (HBsAb), and anti-Hepatitis B virus core protein
antibody (HBcAb) were 5.84%, 41.31%, and 35.92%, respectively, whereas in the group of subjects less than 5 years old,
these prevalences were 1.16%, 46.77%, and 8.69% respectively, which suggests that the Hepatitis B virus (HBV)-carrier
population is decreasing, and the nationwide HBV vaccine program has contributed to the lowered HBV prevalence in the
younger generation in China. Meanwhile, a large deficit remains in coverage provided by the national HBV immune
program. In addition, our data suggested the possibility that HBsAb may not last long enough to protect people from HBV
infection throughout life. The overall prevalence of anti-Hepatitis A virus antibody (anti-HAV) and anti-Hepatitis E virus
antibody (anti-HEV) were as high as 72.87% and 17.66%, respectively. The indices increased with age, which suggests that a
large proportion of Chinese adults are protected by latent infection. Furthermore, the pattern of HEV infection was
significantly different among ethnic groups in China.
Conclusions: Our study provided much important information concerning hepatitis A, B, C, and E prevalence in China and
will contribute to worldwide oversight of viral hepatitis.
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Introduction
Viral infectious diseases are one of the significant challenges to
human healthcare. The increased frequency of emerging new
infectious viral diseases with high mortality in the last decade,
such as SARS, avian influenza A (H5N1), and the most recent
‘‘swine flu,’’ has raised public concern over viral infectious
diseases [1–4]. Viral hepatitis has threatened human health for a
long time with more than one etiologic agent, but this was not
recognized until the 1970s. As a class, these agents include
mainly HAV, HBV, HCV, Hepatitis D virus (HDV), and HEV;
of these, HDV (excluded in this report) only exists with co-
infection with HBV [5–9]. The four hepatitis etiologic agents
belong to entirely different families of viruses. HAV and HEV
always cause acute hepatitis that never develops into a chronic
disease, whereas HCV and HBV always cause chronic hepatitis
and may lead to the development of cirrhosis and hepatocellular
carcinoma [5–9].
HAV is classified in the family Picornaviridae genus Hepatovirus,
with seven genotypes but one serotype, and is transmitted via the
fecal–oral routes [10–13]. Hepatitis A outbreaks occur continually,
with an estimated 1.4 million new infections worldwide annually
[12], and it has decreased in developed regions due to improved
personal and public hygiene and efficient vaccination. In
developing countries, the disease is related to raw food or
contaminated water, which can cause an outbreak at any time
[11].
HEV is classified in the family Hepeviridae genus Hepevirus, with
four major genotypes but one serotype. It has a transmission route
similar to that for HAV and is prevalent in developing countries
[9,14–16]. Fulminant hepatitis E has a mortality rate of 0.5–4.0%
in the general population, except in pregnant women, who may
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8467suffer up to 20% mortality [14–16]. Although a new and effective
recombinant vaccine has recently been developed and tested in the
US [17], in developing countries, Hepatitis E remains an
important health problem.
HBV is classified in the family Hepadnaviridae genus Orthohepad-
navirus, with eight genotypes but one serotype. The virus is
transmitted mainly via blood, body-fluid contact, and vertical
transmission [18,19]. Hepatitis B is estimated to infect 2 billion
people globally, with 350 million chronic cases and 60,000 deaths
each year
18. Hepatitis B vaccine has been available since 1982
and has a high efficacy in the prevention of HBV transmission
[19,20]. Because China is particularly hard hit by HBV, the
Chinese government has made strong efforts to establish a
universal infant immunization program since 1992. Since then,
hepatitis B vaccine coverage has reportedly increased from 30.0%
for newborns in 1992 to 93.4% in 2005 [21].
HCV is classified in the family Flaviviridae genus hepacivirus, with
six major genotypes and multiple serotypes. It was first identified
in 1989 and can be transmitted in a manner similar to HBV [22–
24]. Hepatitis C is generally asymptomatic, with a strong tendency
(up to 80%) for progression to persistent infection [24–27]. Both
HCV and HBV chronically infected patients may progress to
cirrhosis and hepatocellular carcinoma [5]. Unfortunately, no
vaccine is available to date [28,29]. According to estimates from
WHO, that over 170 million people have been infected with
HCV, 3% of the population of the world, with 3 to 4 million new
infections per year and a prevalence rate of 3.9% in the western
pacific region since 1998 [22].
In China, viral hepatitis poses a major public health problem.
Owing to it’s long history, large population, environmental
pollution, and poor hygiene, hepatitis A and E outbreaks and
sporadic incidents occur regularly [11,30]. To date, few investi-
gations of the epidemiology of hepatitis A and E have been
performed, and no complete and precise studies have been
reported. Even with the high rate of hepatitis B, only rare large-
scale population-based studies exist [21]. Furthermore, the 13-
year-long prevention effort involving the vaccination of children
against HBV has not been well assessed. With regard to hepatitis
C, given the WHO estimate of 170 million cases of HCV and 350
million of HBV [18,22], it is reasonable to speculate that HCV
cases should be about half as common clinically as HBV cases.
However, these results are not consistent with the real clinical
situation in China [31]. Furthermore, few large-scale epidemic
data exists to assess the true HCV burden in China and
worldwide. Simply put, viral hepatitis accounts for a very large
proportion of viral diseases in China and the world, notwith-
standing newly emerged viruses for which reliable large-scale
epidemiological surveys and surveillance statistics are lacking.
In this study, in an effort to examine the above-mentioned
issues, we performed a serological cross-sectional investigation of
prevalence of hepatitis A, B, C, and E in 8,762 individuals
throughout Sichuan, Qinghai, Ningxia, Gansu, and Helongjiang
Provinces, as well as in Beijing city. Our study may unravel the
true status of viral hepatitis and provide valuable information
about global surveillance and estimation.
Results
Prevalence of Anti-HCV
Overall prevalence of anti-HCV in 8,762 subjects was 0.58%
(only 51 positive), and the prevalence of anti-HCV in the #5,
#10, #20, #30, #40, #50, #60 and .60 age groups was 0.09%,
0.33%, 0.77%, 0.52%, 0.94%, 0.66%, 0.71%, and 0.42%,
respectively. For those subjects aged between 10 and 60 years of
age, the anti-HCV prevalence was at a relatively high level
(Fig. 1A). For age groups younger than 10, the anti-HCV
Figure 1. Serological features of anti-HCV prevalence in China. Bars represent the number of subjects in each group indicated by left vertical
axis, and the points represent the prevalence in each group indicated by right vertical axis. The horizontal axis represents the age ranges. A, Overall
characterization of anti-HCV by age group. B, Overall characterization of anti-HCV by gender, M, male, F, female. C, Regional characterization of anti-
HCV by age group.
doi:10.1371/journal.pone.0008467.g001
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was found in 1,116 subjects in the #5 group overall), for two main
reasons. First, since HCV identification began in 1989, blood
donor screening for HCV has reduced iatrogenic transmission
through blood transfusion, transplantation, and nosocomial
infections resulting from inadequately sterilized equipments [32].
Second, except for vertical and perinatal transmission, as age
increases, the probability of older groups contacting HCV
becomes greater than for younger groups (Fig. 1A). However, in
the .60 age group, anti-HCV prevalence was also lower, which
may be partially explained by many HCV-related cirrhosis and
hepatocellular carcinoma deaths in this group in China (Fig. 1A)
[33].
The overall prevalence of anti-HCV in 4101 female subjects
was 0.68% (28 positive) which was higher than that in the 4661
male subjects, 0.49% (23 positive). For those subjects younger than
30, the prevalence of anti-HCV in female was lower than that in
male, while this prevalence increased and turned to be higher than
that in male in .30 age groups (Fig. 1B).
With regard to regional differences in the prevalence of anti-
HCV, of 1,647 subjects from Heilongjiang Province, the local
prevalence was 0.55%, consistent with the overall prevalence
described above. The prevalence of anti-HCV in the #30 and the
#60 groups, 0.77% and 1.47%, respectively, was higher than that
in the other age groups (Fig. 1C). In Beijing and Ningxia, the
regional prevalence was 0.16% of 636 subjects and 0.10% of 998
subjects, respectively (Fig. 1C). In Gansu, the regional prevalence
was 0.96% among 1,986 subjects. All 87 subjects in the #5 group
tested negative for anti-HCV, with all positive cases found among
subjects between 5 and 60. The older age range had the highest
rates, with a peak of 1.97% in the #50 group, and the younger age
range showed a small peak of 1.09% in the #20 group (Fig. 1C).
The prevalence of anti-HCV in Qinghai was significantly higher
(1.84%) than in other regions, with the #40 group reaching
2.92%. One positive case was found in the #5 group, accounting
for 14.29% of seven subjects in this age group in this region. The
subject was a boy of one year of age who tested positive for HBsAb
and HBcAb simultaneously. In Sichuan, 930 subjects in the #5
group were tested, and all were negative. Positive results appeared
in the #20, #40, #60, .60 groups, with prevalences of 0.36%,
0.76%, 0.51%, and 0.66%, respectively.
Prevalence of Serologic Markers of HBV
The overall prevalence of HBsAg was 5.84% (512 positive) in
8,762 subjects, which is significantly lower than that reported in
1992 (9.8%) [31], suggesting that the population of HBV carriers
is decreasing. In the #5 group, the prevalence of HBsAg was
1.16%, and the prevalences of HBcAb and HBsAb among this
group were 8.69% and 46.77%, respectively. These results
indicate that strong efforts have been made in younger children
since the HBV infant vaccination was introduced in 1992 and
integrated into the national immunization program in 2002
(Fig. 2A). Moreover, HBIG and HBV vaccine treatment for
newborns of HBV-infected mothers at delivery could also
contribute to the significant reduction of vertical or perinatal
transmission of HBV. In the .60 group, HBsAg prevalence was
also low, probably due to deaths caused by HBV-related cirrhosis
and hepatocellular carcinoma in this group [33] (Fig. 2A).
The prevalence of HBsAb was 41.31% overall (Fig. 2A), which
was different from the prevalence figures for anti-HAV and anti-
HEV (see following section). This percentage showed a relatively
stable level across all age groups, which suggested that HBsAb may
not be as stable as are anti-HAV and anti-HEV. Alternatively, the
increase in anti-HAV and anti-HEV may be due to repeated
Figure 2. Prevalence of HBV serologic markers in China. Bars represent the number of subjects in each group indicated by left vertical axis,
and the points represent the prevalence in each group indicated by right vertical axis. The horizontal axis represents the age ranges. A, Overall
characterization of HBV serologic markers by age range group. B, Overall characterization of HBV serologic markers by gender, M, male, F, female. C,
Regional characterization of HBV serologic markers by age group.
doi:10.1371/journal.pone.0008467.g002
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question as to whether the current HBV vaccination program may
be inadequate. It is of note that although the HBsAg showed
significantly lower prevalence in young generation in our study,
HBsAb was still at 46.77% (Fig. 2A), which is very close to over all
the average (41.31%). Other factors that might contribute to
HBsAb prevalence, including infection acquired through vaccina-
tion, are large numbers of children delivered outside hospital
settings, popular movements opposing HBV vaccination coverage,
or procedural factors including the efficiency of the immunization
program and the quality of the vaccine.
However, HBcAb prevalence increased with age from 8.69% in
the #5 group to 65.16% in the .65 group, with an overall
prevalence 35.92% (Fig. 2A). In contrast to HBsAb, which can be
caused by HBV infection or by vaccination, HBcAb results only
from HBV infection. Comparing HBcAb and HBsAb by age, in
the younger groups, HBcAb prevalence was much lower than was
that for HBsAb, suggesting that HBsAb was mainly caused by the
HBV vaccine. In older groups, HBcAb prevalence increased and
became higher than that for HBsAb, with trends for the
intersecting in the age groups spanning 36–45 years of age
(Fig. 2A). This indicates that both HBsAb and HBcAb were
mainly caused by latent HBV infection. Furthermore, the
difference between prevalence trends for HBsAb and HBcAb
raises the possibility that HBsAb has declined faster than HBcAb,
suggesting a need for precise evaluation of the maintenance of
HBsAb derived from the HBV vaccination program and opens
the possibility that re-vaccination may be required in older
populations.
When the overall prevalence of HBV serologic markers were
stratified by gender, the prevalence of HBsAg, HBsAb and HBcAb
were 6.24%, 43.53% and 37.76% respectively in male subjects,
and were 5.38%, 38.80% and 33.82% respectively in female
subjects. All three serologic markers showed higher prevalence in
male than that in female, although the prevalence of HBsAg
showed mildly higher in female in the subjects older than 45 and
the prevalence of HBsAb in female was higher in the .65 group
(Fig. 2B).
HBV serologic markers showed regional characteristics. In
Beijing, Ningxia, Gansu, and Sichuan, HBsAg prevalence was
consistent with the overall situation mentioned above. In
Heilongjiang and Qinghai, however, HBsAg prevalence was
higher than in the other regions (Fig. 2C). HBsAb prevalence
was higher in younger age groups in Heilongjiang and Sichuan,
which may suggest a better vaccination program for children in
these regions. HBcAb prevalence is high in older groups from all
regions investigated. Especially in Qinghai and Gansu, HBcAb
prevalence remained higher than that of HBsAb, which suggests
that the HBV vaccination is insufficient in these regions and the
prevalence of HBsAb together with HBcAb mainly resulted from
latent HBV infection (Fig. 2C).
Prevalence of Anti-HAV
The overall prevalence of anti-HAV in 8,762 subjects was as
high as 72.87%. Anti-HAV prevalence in #5, #10, #20, #30,
#40, #50, #60, and .60 years age groups was 44.71%, 51.88%,
57.64%, 73.51%, 88.32%, 91.12%, 93.51%, and 97.27%,
respectively. The prevalence of anti-HAV showed an increase
from younger groups (44.71%) to older groups (97.27%) (Fig. 3A).
This high anti-HAV prevalence may result from the long history,
large population, inadequate sanitation, and poor hygiene of
China that may favor HAV circulation and transmission [11]. The
high prevalence in the #5 group may be partially due to the HAV
vaccination. Although the prevalence of anti-HAV in male was
lower than that in female, the over all prevalence of anti-HAV was
very close, that was 72.17% and 73.67% respectively (Fig. 3B).
Figure 3. Serological features of anti-HAV prevalence in China. Bars represent the number of subjects in each group indicated by left vertical
axis, and the points represent the prevalence in each group indicated by right vertical axis. The horizontal axis represents the age ranges. A, Overall
characterization of anti-HAV by age group. B, Overall characterization of anti-HAV by gender, M, male, F, female. C, Regional characterization of anti-
HAV by age group.
doi:10.1371/journal.pone.0008467.g003
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similar tendency, increasing gradually from the #20 to the .60
groups. In the #5 and the #10 groups, the prevalence of anti-
HAV varied regionally. In Heilongjiang, Gansu, and Qinghai
levels were consistently lower. In Beijing and Ningxia, the high
prevalence of anti-HAV may be due to a sampling bias. In
Sichuan, the prevalence of anti-HAV was 48.60% of 930 subjects
in the #5 group and 67.49% of 323 subjects in the #10 group
(Fig. 3C).
Prevalence of Anti-HEV
The overall prevalence of anti-HEV in 8,762 subjects was as
high as 17.66%. Anti-HEV prevalence in #5, #10, #20, #30,
#40, #50, #60, and .60 age groups was 5.38%, 4.20%,
9.75%, 13.20%, 24.23%, 23.70%, 31.52%, and 45.91%,
respectively (Fig. 4A). For subjects younger than 20, the
prevalence of anti-HEV in female subjects showed mildly higher
than that in male, while for those subjects older than 20, the
prevalence in male became higher than that in female (Fig. 4B).
Similar to anti-HAV, the prevalence of anti-HEV increased
significantly in the #10 and #20 age groups and then increased
gradually with age in Heilongjiang, Beijing, Gansu, and Sichuan.
However, the average level was much lower than was that for
anti-HAV.
In Ningxia and Qinghai, the prevalence of anti-HEV was
extremely low regardless of age, with an average prevalence of
0.40% and 0.37%, respectively. This evidence corresponds with
our ongoing study showing that swine are a major reservoir and
source of HEV in China [30]. Ningxia has a primarily Muslim
population, and Qinghai is a Tibetan area; both of these
populations have little contact with swine due to the nature of
their spiritual practices (Fig. 4C).
Discussion
Hepatitis is a major public health burden in China [31], yet
complex epidemiological examinations of hepatitis A, B, C, D, or
E have very rarely been performed. Although viral hepatitis is an
‘‘old’’ problem, the understanding of viral hepatitis remains vague
even as attention is paid to newly emerging and highly pathogenic
viral diseases that have been the recent focus of public health
efforts. Given the vast number of viral hepatitis cases in China
[31], we should not ignore these ‘‘old’’ diseases. In this study, our
epidemiologic survey examined hepatitis A, B, C, and E in 8,762
individuals distributed throughout six regions in China to
demonstrate the general status of viral hepatitis infection on a
regional level and with age-specific profiles to benefit worldwide
hepatitis surveillance.
HAV and HEV infection may result in acute hepatitis with a
certain death rate [11,34]. Our data showed these two viruses
share a similar serological prevalence in China. The overall
positive rates are very high in Han ethnic areas, and the rate tends
to increase with age, suggesting that common transmission routes
may determine common prevalence patterns for these two viruses.
This evidence may contribute to mathematic models for other
infectious diseases in the future [35]. With regard to hepatitis E,
based on our decades-long surveillance, we recognized that HEV
transmission in China is closely related to the presence of swine
(BI’s unpublished data). In areas where people live with swine,
hepatitis E outbreaks are constant. In contrast, in areas in China
where people do not live with swine, hepatitis E rarely occurs,
which suggests that swine constitute a major reservoir and source
of HEV. Although many studies have reported the isolation of
HEV from swine and other animals [36–38], our data are the first
to demonstrate that the prevalence of HEV is related to culture
and religion. However, for hepatitis A, our data show no
Figure 4. Serological features of anti-HEV prevalence in China. Bars represent the number of subjects in each group indicated by left vertical
axis, and the points represent the prevalence in each group indicated by right vertical axis. The horizontal axis represents the age ranges. A, Overall
characterization of anti-HEV by age group. B, Overall characterization of anti-HEV by gender, M, male, F, female. C, Regional characterization of anti-
HEV by age group.
doi:10.1371/journal.pone.0008467.g004
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subjects included a certain number of HAV vaccinated young
individuals, our data showed that among people older than 20
years, the anti-HAV prevalence is more than 60%, and this rises to
nearly 100% in the group over 60 years. These data suggest that
the anti-HAV response detected in a large number of Chinese
people reflects a latent infection.
Large-scale studies on the prevalence of HCV are not well
documented in many countries, especially in developing countries.
Worldwide, 3% of the population has been estimated to be
infected by HCV [22]. In China, specialists and clinicians doubt
this rate, because both epidemiologic studies and random clinical
cases never fit this rate. Although this study had some deficiencies
in subject sampling, our data showed that the overall average
prevalence of anti-HCV was 0.58% in China. Together with data
from our ongoing nationwide HCV serological survey (in which
the overall anti-HCV prevalence is less than 0.5% among more
than 80,000 Chinese subjects (BI’s unpublished data), these
findings lead us to believe that the exact HCV prevalence is
much lower than the WHO estimation indicates. HCV was
identified in 1989, and HCV screening in blood began in the
1990s, a practice that may significantly reduce the transmission
rate of HCV by blood transfusion and other sources of iatrogenic
infection. Therefore, it is reasonable that the transmission and
spread of HCV can be controlled and prevented by strict blood
screening and other procedural measures.
A total of 9.8% of the Chinese population were estimated to be
carriers of HBV in the 1992 national wide HBV survey [31].
Sixteen years have passed since that survey. So what are the
current features of HBV prevalence in China? HBV infant
immunization was introduced in 1992 and integrated into the
national immunization program in 2002. What is the effect of
HBV vaccine and what is the actual status of the HBV
immunization program? Our report answered these questions as
well. Generally, the overall HBsAg prevalence was 5.88% in this
study, which is very close to the nationwide HBV survey
performed on more than 80,000 subjects in 2006 [21]. In the
#5 group, the prevalence rates of HBsAb, HBsAg, and HBcAb
were 46.77%, 1.16%, and 8.69%, respectively, which suggests that
the antibody level of most individuals is raised by HBV
vaccination. With regard to the question of why only 46.7%
individuals in this group are positive for HBsAb, the national
immunization program has not really responded to this question
well. Quality problems with the HBV vaccine and lack of response
to the HBV vaccine are likely the main reasons. The average
HBsAb prevalence is 41.90%, which is different from prevalences
for anti-HAV and anti-HEV. The data showed a tendency for
HBsAb to decline with increasing age, suggesting that HBsAb may
be easily degraded. Our data also raise a query as to whether the
three doses of HBV vaccine given in childhood are enough to
maintain HBV prevention throughout life. Overall, in the present
study, HBcAb tended to increase with increasing age. Together
with the pattern of HBsAg prevalence, these data suggest that for a
majority of Chinese adults, HBsAb resulted mainly from latent
infection.
This was a cross-sectional study performed on large-scale
population. The data-collection process had some shortcomings,
including the failure to collect vaccination histories for subjects
and the problem of bias in sampling. Nevertheless, this study
provided much important information concerning the prevalence
of hepatitis A, B, C, and E in Sichuan, Qinghai, Ningxia, Gansu,
and Helongjiang Provinces as well as Beijing city of China, and we
believe our data reflect a close approximation to the national wide
exact situation of hepatitis infections.
Materials and Methods
Ethics Issues
All aspects of the study were performed in accordance with the
national ethics regulations and approved by ethics committee of
CDC, China as well as local CDC in related province. Study
participants were informed of the study’s purpose and of their right
to keep information confidential. Written consents were obtained
from the participants involving in this study and approved by
ethics committee of local CDC.
Study Subjects and Specimen Collection
The target subjects in this study were the normal Chinese
individuals which were selected to be as representative of the
demographic characteristics as possible in regarding areas of
China. Considering the prevalence of related serologic makers of
hepatitis A, B, C, and E, a total of 8,762 blood samples were
obtained randomly from physical examination participants
distributed throughout Sichuan, Qinghai, Ningxia, Gansu, and
Helongjiang Provinces as well as Beijing city in 2007, in which the
number of male subjects was 4661 and the number of female
subjects was 4101. As multiple ethnicities live in China, and
hepatitis prevalence is different among regions, sampling regions
included two minority areas (Ningxia and Gansu). The vaccination
history of subjects was not considered. A total of 1,647 samples
were collected from Heilongjiang, 636 from Beijing, 998 from
Ningxia (a Muslim area), 1986 from Gansu, 814 from Qinghai (a
Tibetan area), and 2,681 from Sichuan (Fig. 5). Serum was
separated at local laboratories, transported to the National
Hepatitis Laboratory at the Chinese Centers for Disease Control
(CDC) in Beijing, and stored at 240uC until laboratory testing was
performed.
Age Grouping of Subjects
All subjects from each region were grouped by age range: #5,
#10, #20, #30, #40, # 50, #60 and .60 years of age for
epidemic analysis (‘‘#’’ indicated beginning with the older than
the end point of last age range). For HBV epidemiology, age
grouping was based on the national immunization policy for HBV
that was first introduced in 1992 and integrated into the national
immunization program in 2002. Thus, subjects were grouped by
age ranges of #5, #15, #25, #35, #45, #55, and .65years of
age.
Due to random sampling, the number of subjects in each age
group was variable. In particular, Beijing had no subject in the #5
group, and only one and six subjects in the #10 and #20 groups,
respectively. In Ningxia, the .60 group had one subject. In
Qinghai, seven subjects were included in the #5 group, and the
.60 group had no subjects. In Sichuan 930 subjects were in the
#5 group, which was significantly more than the number in the
same age groups in other regions. With regard to the age
groupings for HBV epidemiology, the distribution of subjects in
the #5 group was the same as that mentioned above. Deficiencies
in other age groups included only one subject in the #15 group
and four in the .65 group. In Ningxia and Qinghai, no subjects
were included in the .65 group.
Laboratory Testing
All serum specimens were tested in the National Hepatitis
Laboratory, Institute for Viral Disease Control and Prevention at
the China CDC. A detailed laboratory testing protocol was used,
including a retest of specimens with inconsistent results. Testing
kits were selected based on an evaluation of available enzyme-
linked immunosorbent assay (ELISA) kits in China and compar-
Viral Hepatitis in China
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using a panel of 200 reference serum specimens. ELISA diagnostic
kits for HBV serologic markers, anti-HAV, anti-HCV, and anti-
HEV IgG were all purchased from Beijing Wantai Biological
Pharmacy Enterprise Co., Ltd. (Beijing, China) and used
according to the manufacturer’s instructions.
Data Analysis
All serological prevalence indices and figures in this study were
calculated by Microsoft Office Excel 2003.
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